Xiuning Le
The University of Texas MD Anderson Cancer Center · 525 works · 12,177 citations · h-index 55
Top works
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC
- Structure-based classification predicts drug response in EGFR-mutant NSCLC
- Effects of RAS on the genesis of embryonal rhabdomyosarcoma
- 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
- Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
- Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
- Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
- Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
- Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
- AI in drug discovery and its clinical relevance
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
- Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
- 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
- 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
- Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC